# CODEX Campaign Log - 20260824T134240Z

Run start UTC: 2026-08-24T13:42:40Z (first request of the Episode 11 universe audit)
Run end UTC: 2026-08-27T11:03:56Z (deployment and publication read-back complete)
Agent: CODEX (OpenAI's coding agent)
Sessions: Codex rollouts `rollout-2026-08-24T00-38-11-01a03246-...` and `rollout-2026-08-26T13-51-24-01a03f69-...`
Live target: `6a8cb433e3971b7c87943f11` (**Public Portfolio Challenge: Semis + Biotech**, Public `5OH79160`)

## Source note

Every timestamp below is the UTC timestamp of the Codex session record. Quoted lines are Codex's own
messages, copied verbatim. Central Time is UTC minus 5 hours in this period. Results and IDs come from
those messages and from the addenda Codex wrote. Where a number is not in those sources it is marked
as not recorded.

## Starting point

- Grok Bot had frozen two books (see [`GROK_BOT_CAMPAIGN_LOG.md`](GROK_BOT_CAMPAIGN_LOG.md)): 20
  biotech names on **Public Portfolio Challenge: Biotech** and 7 semis names (S13 A) on **Public
  Portfolio Challenge: Semis**, both cloned live on 2026-08-23 CT.
- Codex did not choose the original names. Its work was auditing them, adapting the books to the
  cash accounts and redesigning the construction.

## Phase 1 - Universe audit and the 17-name cleanup (2026-08-24)

- 13:42:40 Austin asked for deep research on every stock in both portfolios to check they were good
  picks for the thesis. 13:46:56 he narrowed it: "you're mostly auditing if it's a decent company and
  not a shit stock".
- 13:54:42 Codex returned grades for all 27 names. It recommended removing **PSNL** (Tempus acquiring it
  for $16.25 per share), **TECH** (Merck KGaA acquiring it for $73 cash) and **PACB** ("the closest
  thing to a shit stock in the portfolio"). It graded **SDGR** B company / B- stock: "Better business
  than most AI-drug-discovery names because the software revenue is real. Keep small." It found "No
  shit stocks in the current seven" semis.
- 13:55:43 Austin quoted Codex's recommendation and replied "clean these up, perform the
  walk-forward, if it looks good, update the strategies", and asked for 24/7 deployment on both books.
- 14:01:05 Cleaned 17-name biotech book vs the original 20 on matched folds: mean OOS +41.18% vs
  +31.07%, mean Sortino 1.57 vs 1.24, worst drawdown 19.45% vs 25.52%. Studies and detail in
  [`../audits/2026-08-24-biotech-semis-deployment-audit.md`](../audits/2026-08-24-biotech-semis-deployment-audit.md).
- 14:02:16 Live biotech entry strategy replaced with the 17-name cleanup; frequency set to `Constant`.
- 14:08:28 Rejected a 30% MRNA core (mean OOS fell to +21.04%, worst drawdown 39.06%).
- 14:10:30 Rejected a vertical-first variant (mean OOS +7.00%).
- 14:27:50 No-trade diagnosis: Biotech had 562 broker rejections, 560 of them `Option level required`;
  Semis was held by a 63-day cooldown counting canceled July 17 SNDK orders.

## Phase 2 - Spread restriction and short-term debit-spread rule (2026-08-24)

- 14:50:26 Austin: "I can only have 1 margin account. and it's my main account." He asked Codex to
  remove spreads from both new books with the full process.
- 16:21:18 Austin rejected the spread-free books as clearly weaker ("i prefer high returns"), and at
  16:23:43 asked Codex to revert both books to the debit-spread strategies and keep iterating.
- 16:52:22 Austin required that debit spreads always be short term. Result:
  [`addendum/SHORT_TERM_DEBIT_SPREADS_20260824.md`](addendum/SHORT_TERM_DEBIT_SPREADS_20260824.md)
  (180-DTE ceiling, NexusTrade commit `1ea709adfb`).
- 18:33:29 Austin questioned why the RebalanceOption cooldown counted canceled orders from replaced
  strategies, suggested it should behave like DaysSinceOrder, and asked for a fix, test and deploy if
  that was the bug. 18:51:44 Codex confirmed in production that Semis
  then staged an ANET `230/240C` debit spread for approval.

## Phase 3 - Combined $13,500 cash book and failed lockbox (2026-08-24)

- 18:53:12 to 18:59:05 Austin decided to combine the two cash accounts and switch to long calls. His
  instructions: disable the strategies, create a combined chat portfolio, "Feel free to screen new
  stocks... you know the thesis, but you might be able to do even better than Grok", run walk-forward
  and lockbox, deploy if decent.
- 19:01:53 Codex canceled nine unapproved staged legs (Biotech: one SDGR call plus BMY, BNTX and MRK
  verticals; Semis: the ANET vertical) and removed both entry strategies.
- 19:43:41 Three-sleeve finalist (MRNA core, semi momentum, semi pullback): five OOS folds
  +152.2%, +354.6%, -8.8%, +66.2%, +100.7%.
- 19:45:29 "The lockbox rejected v7: **-44.15%**, 82.44% drawdown, six closed trades, four names
  traded. I am not deploying it." Detail in
  [`addendum/COMBINED_LONG_CALL_RESEARCH_20260824.md`](addendum/COMBINED_LONG_CALL_RESEARCH_20260824.md).
- 19:53:18 Optimizer fix for duplicated cooldown conditions, NexusTrade commit `b0dccadba5`.
- 21:09:02 Frozen forward candidate `6a8cb278c57fd738a24f0409` (MRNA core 25%, semi momentum 20%).
- 21:14:27 The combined live portfolio `6a8cb433e3971b7c87943f11` was created by the Public broker
  sync after Austin consolidated the accounts. Codex later fixed a client cache defect and a paper
  deployment classification defect found during that sync (NexusTrade commit `b6fa0192b7`).
- 21:59:04 Combined target verified at $13,500 cash, no holdings, no strategies; frequency corrected
  to `Constant`.

## Phase 4 - Restoring biotech, cutting RXRX/SDGR/BMY, first live deploy (2026-08-24 to 2026-08-25)

- 23:32:35 Austin: "So just MRNA? What about the other biotechs?" 23:36:24: "we obv need to include
  biotech!!! fix this we're not done". Codex had reduced the biotech exposure to MRNA alone.
- 23:56:16 Codex added an XBI sector gate to the 17-name biotech sleeve.
- 00:23:12 to 00:26:33 (Aug 25) Codex tested TEM in place of RXRX and a no-RXRX universe, then kept
  the 16-name chain plus a 25% MRNA core.
- 00:35:05 Austin asked why MRNA was hardcoded and whether it added concentration risk. 00:37:16
  Codex: "I misunderstood 'MRNA is the bet' as an allocation instruction." The dedicated MRNA sleeve
  was removed.
- 00:41:58 Austin asked for deep research on every stock to make sure none was a weak stock and each
  could benefit from the thesis. Result:
  [`addendum/PORTFOLIO_UNIVERSE_AUDIT_20260825.md`](addendum/PORTFOLIO_UNIVERSE_AUDIT_20260825.md).
- **2026-08-25T00:57:41Z, SDGR cut.** Codex: "Removing RXRX, SDGR, and BMY cuts the full replay only
  from 274.91% to 266.38%, while rolling OOS rises from 29.31% mean and 6/7 positive to 45.54% and
  7/7; anchored median rises from 31.82% to 38.67%. SDGR and BMY are not bad companies. They are being
  removed because their transmission from Moderna's result is too loose. RXRX is the only outright
  quality rejection."
- 2026-08-25T01:07:44Z Codex's summary line: "SDGR: legitimate company, weak Moderna transmission."
- 01:10:49 Austin, on a first-person paragraph Codex had drafted narrating its own iterations: "don't
  include this! this was you, not me!" Codex removed it.
- 01:13:02 Austin preferred being able to hold a biotech and a semi at the same time. Codex built
  mixed sleeves with an SMH 100-day gate on semis.
- 02:07:00 Codex refused to deploy because the only valid lockbox had failed. 02:12:13 Austin: "i'm
  not waiting 90 days to capitalize on news that's happening right now." 02:12:48: "do it."
- 02:16:11 Six-strategy sector-gated finalist cloned to the live account (Aug 24, 9:16 PM CT): a
  14-name biotech sleeve gated by XBI, a 6-name semis sleeve (NVDA, ANET, KLAC, TSM, MRVL, LRCX)
  gated by SMH, `Constant`, manual approval. It was a forward deployment, not a certified one.
- 03:07:23 Codex recreated Grok Bot's two original books as paper portfolios from archived share
  snapshots ("Original Grok Paper").
- 13:30:01 The live book staged a QGEN Dec 2027 $45 call at $4.10 and an ADPT Apr 2027 $30 call for
  approval. The QGEN order filled at $5.90 at 13:38:00. The ADPT order was canceled.

## Phase 5 - Redesign and SDGR restored (2026-08-26)

- 18:51:31 Austin asked why the book was not trading. 18:57:56 Codex: semis had selected ANET, and the
  SMH gate (SMH $556.13 vs 100-day SMA $590.02) blocked it; biotech was inside its 7-day cooldown.
- 19:27:35 Austin objected to sector-wide gating and asked for company-level filters instead. 19:49:22
  he asked for a complete redesign: root-cause the drawdowns from real orders and rebuild around each
  company and the actual thesis.
- **2026-08-26T20:03:51Z, SDGR restored.** After reading the published article, Codex wrote: "More
  importantly, the funded rebuild dropped several of the names that most directly expressed that
  thesis: PSNL/TEM, RXRX, SDGR, PACB, TECH, and BMY. The semiconductor rebuild also dropped AVGO and
  AMAT from the original seven-name book and introduced KLAC." And: "I'm treating that thesis drift as
  a first-class redesign problem."
- 20:10:09 Redesign universe: Grok Bot's 20 biotech names, TEM, Grok Bot's 7 semis and KLAC (29).
- 20:25:40 Six-sleeve Candidate F (anchored OOS mean +8.98%, 3 of 5 positive). 20:59:48 Austin: "the
  redesign isn't good." 21:00:17 Codex rejected F and proposed MRNA and ANET cores "because those are
  the two names you personally singled out". 21:19:56 Austin: "what the?" 21:20:10 Codex withdrew it:
  "I converted conversational emphasis into a conviction hierarchy you never gave me."
- 21:32:23 Codex proposed a stock-led portfolio. 21:48:08 Austin rejected it. 21:48:21 Codex: "I
  should not have proposed a stock portfolio."
- 22:23:49 First options-only finalist reported as not deployable because the walk-forward was
  corrupted. 22:29:22 Austin: "Don't stop until its impossible or its deployable and robust and
  intrepretable".
- 22:31:51 Root cause: the research portfolio had `initialValue = 0`, so walk-forward folds produced
  NaN and false no-signal results. Fixed in NexusTrade commit `a8f4b169d9`.
- 22:40:21 Austin: "why 25,000? i dont have that much in the fucking portfolio". All sizing was rerun
  at $13,500.
- 22:48:27 Weak fold traced to orders: RXRX, NVDA, LRCX, SDGR, ILMN and MRK were the largest losers;
  ANET made about +$1,750.
- 23:40:27 Austin: "we do NOT need to be profitable 5/5 folds."
- 23:56:44 UTF-8 truncation panic in breadth audits found; fixed in NexusTrade commit `32c9c377ef`.
- 23:59:08 Finalist: one central allocator, 39% gross-exposure entry gate. OOS +42.87%, +25.00%,
  -2.22%, +9.95%, +65.40%; median Sortino 1.99; worst OOS drawdown 22.47%.
- 2026-08-27 00:00:32 Empty-book snapshot at $13,500 resolved NVDA, QGEN, RXRX and PACB calls.
- 00:01:46 Full replay: +252.37%, Sortino 2.02, max drawdown 29.79%, median deployment 30.5%.
- 00:07:22 Memo pushed: [`addendum/EPISODE_11_OPTIONS_PORTFOLIO_REDESIGN_20260826.md`](addendum/EPISODE_11_OPTIONS_PORTFOLIO_REDESIGN_20260826.md).

### Final universe

26 names: Grok Bot's 20 biotech names minus PSNL, plus Grok Bot's 7 semis. Codex's draft recorded
the two exclusions from its 29-name redesign set: PSNL "because the announced Tempus acquisition
makes it a deal-capped situation", and KLAC "because it was not in the original frozen semiconductor
thesis universe". TEM was also left out; the reason is not recorded. SDGR, RXRX and BMY, cut on
Aug 25, are back in.

## Phase 6 - Live deployment (2026-08-26 CT)

- 01:56:03 (Aug 27 UTC) Austin: "why would it not be deployed wtf?????"
- 02:02:08 Austin: "move the current strategies to another paper portfolio and replace with this one".
- 02:04:13 Legacy six-strategy book preserved as paper portfolio `6a8f9b0ec67c177db82d5b0f`.
- 02:05:11 Live strategy set replaced: 6 removed, 29 added, all matching the validated source
  `6a8f7ea36c9d5ad71a63775d`. QGEN call preserved. Portfolio and strategy automatic approvals off.
- 02:05:57 Current-book reconciliation `6a8f9b603a0c760d5849f380`: NAV $13,335.02, target was the
  existing QGEN contract, zero orders, $0 estimated cost.
- 02:19:41 Austin authorized the Medium and public-description updates. 11:03:56 publication
  read-back complete.

## Ledger of live strategy sets on `6a8cb433e3971b7c87943f11`

| Period (UTC) | Strategy set | Source |
| --- | --- | --- |
| 2026-08-24 21:14 to 2026-08-25 02:16 | none (cash only) | broker sync |
| 2026-08-25 02:16 to 2026-08-27 02:05 | six strategies, XBI-gated biotech + SMH-gated semis | Codex, Phase 4 |
| 2026-08-27 02:05 onward | 29 strategies, one 26-company allocator + 28 exits | Codex, Phase 6 |

## Engine defects found and fixed during the campaign

- RebalanceOption cooldown counted canceled orders from replaced strategies (fixed 2026-08-24).
- Optimizer appended a second cooldown instead of replacing it, commit `b0dccadba5`.
- Portfolio list kept stale browser snapshots after sync; paper controls kept live deployment fields,
  commit `b6fa0192b7`.
- Walk-forward accepted zero starting capital, commit `a8f4b169d9`.
- Breadth-audit truncation split multibyte characters, commit `32c9c377ef`.

## Final decision

DEPLOY (owner-directed). The 26-company allocator replaced the sector-gated book on the live account
on 2026-08-26 CT. It passed 4 of 5 OOS folds at $13,500 but has no untouched lockbox; the only valid
combined-book lockbox failed on 2026-08-24. Forward results are in
[`FORWARD_TEST_LOG.md`](FORWARD_TEST_LOG.md).
